# OnCo record eilean-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/eilean-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "eilean-therapeutics" ;
  schema:name "Eilean Therapeutics"@en ;
  schema:alternateName "Eilean Therapeutics Inc."@en, "Eilean Therapeutics AU Pty Ltd"@en ;
  schema:description "Eilean Therapeutics designs tablet medicines for blood cancers that are built to keep working when the cancer mutates; its first drug in people targets the faulty JAK2 protein behind polycythaemia vera and myelofibrosis."@en ;
  schema:url <https://onco.cc/companies/eilean-therapeutics/>, <https://www.eileanther.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.eileanther.com/>, <https://www.eileanther.com/pipeline>, <https://clinicaltrials.gov/study/NCT07527221> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/polycythaemia-vera/>, <https://onco.cc/cancers/primary-myelofibrosis/>, <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/menin/> .